Cas 1073485-20-7 LDC000067 CDK Inhibitors CDK9 Inhibitor
Cas 1073485-20-7 LDC000067 CDK Inhibitors CDK9 Inhibitor
+ AII PRODUCTS
- Prostaglandins - Custom Synthesis - PARP Inhibitors - PI3K Inhibitors - FAK Inhibitors - AKT Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - c-Met Inhibitors - CDK Inhibitors - CYP17 Inhibitors - DNA/RNA Inhibitors - mTOR Inhibitors - SRC Inhibitors - Others
Product
|
Size |
Price |
Stock |
Quantity |
|---|---|---|---|
|
Get Quotation Now Add to Cart Bulk Inquiry |
|||
AddThis Sharing Buttons
Share to FacebookFacebookShare to TwitterTwitterShare to PrintPrintShare to EmailEmailShare to PinterestPinterestShare to GmailGmailShare to LinkedInLinkedInShare to Email AppEmail AppShare to TumblrTumblrShare to MoreAddThis
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
|
Product name:LDC000067 |
Purity:98% min |
|
CAS NO:1073485-20-7 |
Solubility:DMSO47 mg/mL (126.88 mM) |
|
Molecular Formula:C18H18N4O3S |
Package:Package according to customer requirements |
|
Molecular Weight:370.426 |
Storage:Store at -20℃ |
Quality control
Remarks
LDC000067 is a potent and selective CDK9 inhibitor. LDC000067 inhibited in vitro transcription in an ATP-competitive and dose-dependent manner. Gene expression profiling of cells treated with LDC000067 demonstrated a selective reduction of short-lived mRNAs, including important regulators of proliferation and apoptosis. Analysis of de novoRNA synthesis suggested a wide ranging positive role of CDK9. At the molecular and cellular level, LDC000067 reproduced effects characteristic of CDK9 inhibition such as enhanced pausing of RNA polymerase II on genes and, most importantly, induction of apoptosis in cancer cells.
Related Products
BMS-265246; Ribociclib; SU9516; Purvalanol A; Alvocidib; AZD-5597; Kenpaullone; ON123300; BS-181; JSH-150; Riviciclib
References
[1].Albert TK, et al. Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor. Br J Pharmacol. 2014 Jan;171(1):55-68.
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.